Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial (Q88123697)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 June 2014

Language	Label	Description	Also known as
English	Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial	scientific article published on 17 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

object named as

Ignace Vergote

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Andres Redondo Sanchez

1 reference

ORCID Public Data File 2021

Keiichi Fujiwara

5

object named as

Keiichi Fujiwara

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Isabelle Ray-Coquard

8

object named as

Isabelle Ray-Coquard

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Bradley J. Monk

1

object named as

Bradley J Monk

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Andrés Poveda

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Francesco Raspagliesi

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Duk-Soo Bae

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Ana Oaknin

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Diane M Provencher

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Beth Y Karlan

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Catherine Lhommé

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Gary Richardson

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Dolores Gallardo Rincón

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Robert L Coleman

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Thomas J Herzog

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Christian Marth

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Arija Brize

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Michel Fabbro

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Andrés Redondo

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Aristotelis Bamias

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Marjan Tassoudji

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lynn Navale

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Douglas J Warner

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Amit M Oza

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

17 June 2014

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

799-808

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Latest research and treatment of advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and management of edema associated with trebananib (AMG 386).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability and validity of the functional assessment of cancer therapy-ovarian.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Detecting an overall survival benefit that is derived from progression-free survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimizing treatment of the partially platinum-sensitive ovarian cancer patient

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970244-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70244-X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24950985%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q88123697&oldid=2032768612"